Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE ε4 carriers

Journal of Alzheimer's Disease

Volumn 36, Issue 3, 2013, Pages 563-570

  Duits, Flora H ^a   Kester, Maartje I ^a   Scheffer, Peter G ^b   Blankenstein, Marinus A ^b   Scheltens, Philip ^a   Teunissen, Charlotte E ^b   Van Der Flier, Wiesje M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; apolipoprotein E 4; cerebrospinal fluid biomarkers; longitudinal study; oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; ISOPROSTANE DERIVATIVE; TAU PROTEIN;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; GENOTYPE; HETEROZYGOTE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NERVE DEGENERATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 84881471719     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122227     Document Type: Article

References (36)

1. Raber J, Huang Y, Ashford JW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 25, 641-650
2. Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM (2009) CSF biomarkers in Alzheimer's disease and controls: Associations with APOE genotype are modified by age. J Alzheimers Dis 16, 601-607
3. Popp J, Lewczuk P, Frommann I, Kolsch H, Kornhuber J, Maier W, Jessen F (2010) Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: Effects of age and the APOE e4 genotype. J Alzheimers Dis 22, 459-468
4. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM (2004) Cerebrospinal fluid beta-Amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE e4 allele. Biol Psychiatry 56, 670-676
5. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67, 122-131
6. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283
7. Anoop S, Misra A, Meena K, Luthra K (2010) Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases. Indian J Med Res 132, 363-378
8. Lanterna LA, Ruigrok Y, Alexander S, Tang J, Biroli F, Dunn LT, Poon WS (2007) Meta-Analysis of APOE genotype and subarachnoid hemorrhage: Clinical outcome and delayed ischemia. Neurology 69, 766-775
9. Zhou W, Xu D, Peng X, Zhang Q, Jia J, Crutcher KA (2008) Meta-Analysis of APOE4 allele and outcome after traumatic brain injury. J Neurotrauma 25, 279-290
10. Pearson-Fuhrhop KM, Cramer SC (2010) Genetic influences on neural plasticity. PM R 2, S227-S240
11. Ophir G, Amariglio N, Jacob-Hirsch J, Elkon R, Rechavi G, Michaelson DM (2005) Apolipoprotein E4 enhances brain inflammation by modulation of the NF-kappaB signaling cascade. Neurobiol Dis 20, 709-718
12. Olgiati P, Politis A, Malitas P, Albani D, Dusi S, Polito L, De MS, Zisaki A, Piperi C, Stamouli E, Mailis A, Batelli S, Forloni G, De RD, Kalofoutis A, Liappas I, Serretti A (2010) APOE e4 allele and cytokine production in Alzheimer's disease. Int J Geriatr Psychiatry 25, 338-344
13. Pratico D, Lawson JA, Rokach J, FitzGerald GA (2001) The isoprostanes in biology and medicine. Trends Endocrinol Metab 12, 243-247
14. Montine TJ, Markesbery WR,Morrow JD, Roberts LJ (1998) Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44, 410-413
15. Pratico D, MY LV, Trojanowski JQ, Rokach J, FitzGerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB J 12, 1777-1783
16. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, MorrowJD(1999) Increased CSF F2-isoprostane concentration in probable AD. Neurology 52, 562-565
17. Yao Y, Zhukareva V, Sung S, Clark CM, Rokach J, Lee VM, Trojanowski JQ, Pratico D (2003) Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology 61, 475-478
18. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L,DeSS, Zinkowski R, Mehta P, Pratico D, Saint Louis LA,Wallin A, Blennow K, de Leon MJ (2009) Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 30, 682-690
19. Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF (2001) Cerebrospinal fluid abeta42, tau, and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med 125, 510-512
20. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA (2000) Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48, 809-812
21. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, TsuiW, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, De Bernadis JF, Kerkman DJ, Hampel H, Wahlund LO, Davies P (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27, 394-401
22. de Leon MJ, Mosconi L, Li J, De SS, Yao Y, Tsui WH, Pirraglia E, Rich K, Javier E, Brys M, Glodzik L, Switalski R, Saint Louis LA, Pratico D (2007) Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol 254, 1666-1675
23. Quinn JF,Montine KS, Moore M, MorrowJD, Kaye JA,Montine TJ (2004) Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis 6, 93-97
24. Kester MI, Scheffer PG,Koel-Simmelink MJ,TwaalfhovenH, Verwey NA, Veerhuis R, Twisk JW, Bouwman FH, Blankenstein MA, Scheltens P, Teunissen C, van der FlierWM(2012) Serial CSF sampling in Alzheimer's disease: Specific versus non-specific markers. Neurobiol Aging 33, 1591-1598
25. Mosconi L, De SS, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich KE, Switalski R, Mehta PD, Pratico D, Zinkowski R, Blennow K, de Leon MJ (2008) Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 63, 609-618
26. McKhann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
27. PetersenRC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194
28. Mulder C,VerweyNA, van der FlierWM,Bouwman FH,Kok A, van Elk EJ, Scheltens P, BlankensteinMA(2010) Amyloidbeta (1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253
29. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, Frangione B, Ghiso J (2000) Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J 348, 359-365
30. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499
31. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L (1999) The role of APOE e4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 282, 40-46
32. Caselli RJ, Dueck AC, Locke DE, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM (2011) Cerebrovascular risk factors and preclinical memory decline in healthy APOE e4 homozygotes. Neurology 76, 1078-1084
33. Peila R, White LR, Petrovich H, Masaki K, Ross GW, Havlik RJ, Launer LJ (2001) Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: The Honolulu-Asia aging study. Stroke 32, 2882-2889
34. Kester MI, van der Flier WM, Mandic G, Blankenstein MA, Scheltens P, MullerM(2010) Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease. J Alzheimers Dis 20, 1083-1090
35. Glodzik-Sobanska L, Pirraglia E, Brys M, De SS, Mosconi L, Rich KE, Switalski R, Saint LL, Sadowski MJ, Martiniuk F, Mehta P, Pratico D, Zinkowski RP, Blennow K, de Leon MJ (2009) The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging 30, 672-681
36. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, GreggKM,Liu E, Lieberburg I, Schenk D, Black R, Grundman M (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070